Core Viewpoint - Elutia Inc. has granted equity awards to three new employees as part of its 2026 Inducement Award Plan, which is in compliance with Nasdaq Listing Rule 5635(c)(4) [1][2]. Group 1: Equity Awards - The three new employees received a total of 460,000 non-qualified stock options [2]. - The options vest 25% on the first anniversary of the vesting commencement date, with the remaining balance vesting in equal monthly installments over the next three years, contingent on continued employment [2]. - The exercise price for the options is set at $1.09 per share, which reflects the closing price of Elutia's common stock on the grant date [2]. Group 2: Company Overview - Elutia specializes in developing and commercializing drug-eluting biomatrix products aimed at enhancing compatibility between medical devices and patients [3]. - The company is focused on addressing the needs of a growing population requiring implantable technologies, with a mission to humanize medicine for better patient outcomes [3].
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)